Swiss Pharmaceuticals CLENODROL 50mg 50 Caps

Description

Swiss Pharmaceuticals CLENODROL 50mg 50 Caps is a specialist multi-compound capsule product combining SR9009, LGD-4033 and S-4 Andarine in one formula.

Each original container provides 50 capsules. According to the manufacturer’s current product information, one capsule contains 10 mg of SR9009, 15 mg of LGD-4033 and 25 mg of S-4 Andarine, providing a total declared active-compound specification of 50 mg per capsule. Gelatin and magnesium stearate are listed as additional ingredients.

Three-compound formula

The declared formula includes:

• SR9009 Stenabolic – 10 mg
• LGD-4033 Ligandrol – 15 mg
• S-4 Andarine – 25 mg
• Total declared amount – 50 mg per capsule
• Package size – 50 capsules
• Product form – capsules

Although CLENODROL is marketed as a SARM stack, its ingredients do not all belong to the same compound category. LGD-4033 and Andarine are selective androgen receptor modulators, while SR9009 is an experimental synthetic REV-ERB agonist rather than a SARM. Published research concerning SR9009 is predominantly preclinical, and some studies indicate that its biological activity may not be limited to REV-ERB signalling.

Important product identification

Despite the product name, the manufacturer’s declared formula lists SR9009, LGD-4033 and S-4 Andarine. It does not list clenbuterol as an ingredient. CLENODROL should therefore not be described as a clenbuterol product.

A complete catalogue listing should allow customers to verify:

• the Swiss Pharmaceuticals branding,
• the CLENODROL product name,
• the 50-capsule package size,
• the declared amount of each compound,
• the complete ingredient panel,
• the batch and expiry details,
• the product verification code,
• the condition of the original safety seal.

The physical packaging should remain the primary source for the final composition, storage requirements and warning information. Do not distribute a container when the seal is damaged, the label appears altered or its specifications differ from the online description.

Responsible catalogue information

Commercial descriptions frequently associate CLENODROL with fat reduction, improved muscle definition, increased strength or enhanced athletic performance. These promotional claims should not be presented as guaranteed, medically approved or clinically established effects of the commercial product.

A responsible catalogue description should focus on verifiable information such as the compound names, declared amounts, capsule count, packaging and authenticity details. It should not include dosing instructions, cycle recommendations, stacking guidance or claims that the product is free from adverse effects.

Safety and regulatory information

LGD-4033 and S-4 Andarine are unapproved investigational SARMs. FDA materials identify LGD-4033 and Andarine as unapproved new drugs and warn that products containing SARMs have been associated with serious risks, including liver injury and an increased risk of heart attack or stroke.

The inclusion of multiple experimental compounds in one capsule should not be interpreted as evidence of improved effectiveness, safety or suitability for a particular person.

Information for tested athletes

LGD-4033, Andarine and SR9009 are covered by the World Anti-Doping Agency’s 2026 Prohibited List. Athletes and other individuals subject to anti-doping testing should treat the entire CLENODROL formula as prohibited in sport.

This description is provided solely for accurate product identification and catalogue-reference purposes. It does not provide medical advice, instructions for use or a guarantee of physical or performance-related results.